IL10 and mantle cell lymphoma: Accordingly, plasma concentrations of M-CSF and IL-10 are higher in MCL patients and peripheral blood monocyte-expressed CD163 is decreased in MCL patients that responded to combination treatment of ibrutinib and an anti-CD20 antibody [210].